|
1
|
Muto A, Model L, Ziegler K, Eghbalieh SD
and Dardik A: Mechanisms of vein graft adaptation to the arterial
circulation: Insights into the neointimal algorithm and management
strategies. Circ J. 74:1501–1512. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dilley RJ, McGeachie JK and Tennant M: The
role of cell proliferation and migration in the development of a
neo-intimal layer in veins grafted into arteries, in rats. Cell
Tissue Res. 269:281–287. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Guo H, Makarova N, Cheng YES, Ji RR, Zhang
C, Farrar P and Tigyi G: The early- and late stages in phenotypic
modulation of vascular smooth muscle cells: Differential roles for
lysophosphatidic acid. Biochim Biophys Acta. 1781:571–581. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wolff RA, Malinowski RL, Heaton NS,
Hullett DA and Hoch JR: Transforming growth factor-beta1 antisense
treatment of rat vein grafts reduces the accumulation of collagen
and increases the accumulation of h-caldesmon. J Vasc Surg.
43:1028–1036. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jeremy JY, Nystrom ML, Barradas MA and
Mikhailidis DP: Eicosanoids and septicaemia. Prostaglandins Leukot
Essent Fatty Acids. 50:287–297. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sasaki Y, Suehiro S, Becker AE, Kinoshita
H and Ueda M: Role of endothelial cell denudation and smooth muscle
cell dedifferentiation in neointimal formation of human vein grafts
after coronary artery bypass grafting: Therapeutic implications.
Heart. 83:69–75. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yamashita A, Hanna AK, Hirata S, Dardik A
and Sumpio BE: Antisense basic fibroblast growth factor alters the
time course of mitogen-activated protein kinase in arterialized
vein graft remodeling. J Vasc Surg. 37:866–873. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jia G, Cheng G, Gangahar DM and Agrawal
DK: Involvement of connexin 43 in angiotensin II-induced migration
and proliferation of saphenous vein smooth muscle cells via the
MAPK-AP-1 signaling pathway. J Mol Cell Cardiol. 44:882–890. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Libby P, Schwartz D, Brogi E, Tanaka H and
Clinton SK: A cascade model for restenosis. A special case of
atherosclerosis progression. Circulation. 86:(6 Suppl).
III47–III52. 1992.PubMed/NCBI
|
|
10
|
Lyon CA, Johnson JL, Williams H,
Sala-Newby GB and George SJ: Soluble N-cadherin overexpression
reduces features of atherosclerotic plaque instability.
Arterioscler Thromb Vasc Biol. 29:195–201. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bhardwaj S, Roy H and Ylä-Herttuala S:
Gene therapy to prevent occlusion of venous bypass grafts. Expert
Rev Cardiovasc Ther. 6:641–652. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ekstrand J, Razuvaev A, Folkersen L, Roy J
and Hedin U: Tissue factor pathway inhibitor-2 is induced by fluid
shear stress in vascular smooth muscle cells and affects cell
proliferation and survival. J Vasc Surg. 52:167–175. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chan J, Prado-Lourenco L, Khachigian LM,
Bennett MR, Di Bartolo BA and Kavurma MM: TRAIL promotes VSMC
proliferation and neointima formation in a FGF-2-, Sp1
phosphorylation-, and NFkappaB-dependent manner. Circ Res.
106:1061–1071. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Earley S and Brayden JE: Transient
receptor potential channels and vascular function. Clin Sci.
119:19–36. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jia G, Mitra AK, Gangahar DM and Agrawal
DK: Regulation of cell cycle entry by PTEN in smooth muscle cell
proliferation of human coronary artery bypass conduits. J Cell Mol
Med. 13:547–554. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mitra AK, Jia G, Gangahar DM and Agrawal
DK: Temporal PTEN inactivation causes proliferation of saphenous
vein smooth muscle cells ofhuman CABG conduits. J Cell Mol Med.
13:177–187. 2009.PubMed/NCBI
|
|
17
|
Dong LH, Wen JK, Liu G, McNutt MA, Miao
SB, Gao R, Zheng B, Zhang H and Han M: Blockade of the
Ras-extracellular signal-regulated kinase 1/2 pathway is involved
in smooth muscle 22 alpha-mediated suppression of vascular smooth
muscle cell proliferation and neointima hyperplasia. Arterioscler
Thromb Vasc Biol. 30:683–691. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Maile LA, Allen LB, Hanzaker CF, Gollahon
KA, Dunbar P and Clemmons DR: Glucose regulation of thrombospondin
and its role in the modulation of smooth muscle cell proliferation.
Exp Diabetes Res. 2010(pii): 6170522010.PubMed/NCBI
|
|
19
|
Chiu JJ, Usami S and Chien S: Vascular
endothelial responses to altered shear stress: Pathologic
implications for atherosclerosis. Ann Med. 41:19–28. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Panchatcharam M, Miriyala S, Yang F,
Leitges M, Chrzanowska-Wodnicka M, Quilliam LA, Anaya P, Morris AJ
and Smyth SS: Enhanced proliferation and migration of vascular
smooth muscle cells in response to vascular injury under
hyperglycemic conditions is controlled by beta3 integrin signaling.
Int J Biochem Cell Biol. 42:965–974. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Isenovic ER, Kedees MH, Haidara MA,
Trpkovic A, Mikhailidis DP and Marche P: Involvement of ERK1/2
kinase in insulin-and thrombin-stimulated vascular smooth muscle
cell proliferation. Angiology. 61:357–364. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Furgeson SB, Simpson PA, Park I, Vanputten
V, Horita H, Kontos CD, Nemenoff RA and Weiser-Evans MC:
Inactivation of the tumour suppressor, PTEN, in smooth muscle
promotes a pro-inflammatory phenotype and enhances neointima
formation. Cardiovasc Res. 86:274–282. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Egler RA, Fernandes E, Rothermund K,
Sereika S, de Souza-Pinto N, Jaruga P, Dizdaroglu M and Prochownik
EV: Regulation of reactive oxygen species, DNA damage, and c-Myc
function by peroxiredoxin 1. Oncogene. 24:8038–8050. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jamaluddin M, Wiktorowicz JE, Soman KV,
Boldogh I, Forbus JD, Spratt H, Garofalo RP and Brasier AR: Role of
peroxiredoxin 1 and peroxiredoxin 4 in protection of respiratory
syncytial virus-induced cysteinyl oxidation of nuclear cytoskeletal
proteins. J Virol. 84:9533–9545. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gong F, Hou G, Liu H and Zhang M:
Peroxiredoxin 1 promotes tumorigenesis through regulating the
activity of mTOR/p70S6K pathway in esophageal squamous cell
carcinoma. Med Oncol. 32:4552015.PubMed/NCBI
|
|
26
|
Taniuchi K, Furihata M, Hanazaki K,
Iwasaki S, Tanaka K, Shimizu T, Saito M and Saibara T:
Peroxiredoxin 1 promotes pancreatic cancer cell invasion by
modulating p38 MAPK activity. Pancreas. 44:331–340. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou J, Liu Q, Wang J, Guo X and Song L:
Expressions of peroxiredoxin 1, peroxiredoxin 6 and GFAP in human
brain astrocytoma and their clinical significance. Nan Fang Yi Ke
Da Xue Xue Bao. 32:1255–1259. 2012.(In Chinese). PubMed/NCBI
|
|
28
|
Riddell JR, Bshara W, Moser MT, Spernyak
JA, Foster BA and Gollnick SO: Peroxiredoxin 1 controls prostate
cancer growth through Toll-like receptor 4-dependent regulation of
tumor vasculature. Cancer Res. 71:1637–1646. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Riddell JR, Wang XY, Minderman H and
Gollnick SO: Peroxiredoxin 1 stimulates secretion of
proinflammatory cytokines by binding to TLR4. J Immunol.
184:1022–1030. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jiang H, Wu L, Mishra M, Chawsheen HA and
Wei Q: Expression of peroxiredoxin 1 and 4 promotes human lung
cancer malignancy. Am J Cancer Res. 4:445–460. 2014.PubMed/NCBI
|
|
31
|
Hwang KE, Park DS, Kim YS, Kim BR, Park
SN, Lee MK, Park SH, Yoon KH, Jeong ET and Kim HR: Prx1 modulates
the chemosensitivity of lung cancer to docetaxel through
suppression of FOXO1-induced apoptosis. Int J Oncol. 43:72–78.
2013.PubMed/NCBI
|
|
32
|
Sun QK, Zhu JY, Wang W, Lv Y, Zhou HC, Yu
JH, Xu GL, Ma JL, Zhong W and Jia WD: Diagnostic and prognostic
significance of peroxiredoxin 1 expression in human hepatocellular
carcinoma. Med Oncol. 31:7862014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ha B, Kim EK, Kim JH, Lee HN, Lee KO, Lee
SY and Jang HH: Human peroxiredoxin 1 modulates TGF-β1-induced
epithelial-mesenchymal transition through its peroxidase activity.
Biochem Biophys Res Commun. 421:33–37. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Du ZX, Yan Y, Zhang HY, Liu BQ, Gao YY,
Niu XF, Guan Y, Meng X and Wang HQ: Suppression of MG132-mediated
cell death by peroxiredoxin 1 through influence on ASK1 activation
in human thyroid cancer cells. Endocr Relat Cancer. 17:553–560.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jones FS, Meech R, Edelman DB, Oakey RJ
and Jones PL: Prx1 controls vascular smooth muscle cell
proliferation and tenascin-C expression and is upregulated with
Prx2 in pulmonary vascular disease. Circ Res. 89:131–138. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jin L, Kern MJ, Otey CA, Wamhoff BR and
Somlyo AV: Angiotensin II, focal adhesion kinase, and PRX1 enhance
smooth muscle expression of lipoma preferred partner and its newly
identified binding partner palladin to promote cell migration. Circ
Res. 100:817–825. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pi Y, Zhang LL, Li BH, Guo L, Cao XJ, Gao
CY and Li JC: Inhibition of reactive oxygen species generation
attenuates TLR4-mediated proinflammatory and proliferative
phenotype of vascular smooth muscle cells. Lab Invest. 93:880–887.
2013. View Article : Google Scholar : PubMed/NCBI
|
